Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.
van der Hoek S, Koomen JV, van Bommel EJM, Mosterd CM, Scholtes RA, Hesp AC, Stevens J, van Raalte DH, Heerspink HJL. van der Hoek S, et al. Among authors: van bommel ejm, van raalte dh. J Pers Med. 2023 Apr 27;13(5):747. doi: 10.3390/jpm13050747. J Pers Med. 2023. PMID: 37240917 Free PMC article.
Understanding EMPA-REG OUTCOME.
Muskiet MH, van Raalte DH, van Bommel EJ, Smits MM, Tonneijck L. Muskiet MH, et al. Among authors: van bommel ej, van raalte dh. Lancet Diabetes Endocrinol. 2015 Dec;3(12):928-9. doi: 10.1016/S2213-8587(15)00424-6. Lancet Diabetes Endocrinol. 2015. PMID: 26590679 No abstract available.
Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes.
Muskiet MHA, van Bommel EJ, van Raalte DH. Muskiet MHA, et al. Among authors: van bommel ej, van raalte dh. Lancet Diabetes Endocrinol. 2016 Mar;4(3):188-189. doi: 10.1016/S2213-8587(15)00457-X. Epub 2015 Nov 25. Lancet Diabetes Endocrinol. 2016. PMID: 26620250 No abstract available.
Renoprotection in LEADER and EMPA-REG OUTCOME.
Muskiet MH, Tonneijck L, van Bommel EJ, Smits MM, van Raalte DH. Muskiet MH, et al. Among authors: van bommel ej, van raalte dh. Lancet Diabetes Endocrinol. 2016 Oct;4(10):812-4. doi: 10.1016/S2213-8587(16)30214-5. Lancet Diabetes Endocrinol. 2016. PMID: 27663955 No abstract available.
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH. van Bommel EJM, et al. Among authors: van raalte dh. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. doi: 10.2215/CJN.06080616. Epub 2017 Mar 2. Clin J Am Soc Nephrol. 2017. PMID: 28254770 Free PMC article. Review.
SGLT2 inhibition: a new era in renoprotective medicine?
Muskiet MHA, Heerspink HJL, van Raalte DH. Muskiet MHA, et al. Among authors: van raalte dh. Lancet Diabetes Endocrinol. 2017 Aug;5(8):569-571. doi: 10.1016/S2213-8587(17)30222-X. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666776 No abstract available.
Renal outcomes in CVOTs: keep calm and carry on.
Muskiet MHA, van Baar MJB, Scholtes RA, van Raalte DH. Muskiet MHA, et al. Among authors: van baar mjb, van raalte dh. Lancet Diabetes Endocrinol. 2018 Sep;6(9):674-676. doi: 10.1016/S2213-8587(18)30195-5. Epub 2018 Jun 21. Lancet Diabetes Endocrinol. 2018. PMID: 29937268 No abstract available.
210 results